Secondary analysis of the Euro Ewing 2012 trial emulating a target trial: in Ewing sarcoma, VDC/IE induction dose reduction (HR 0.69, 95% CI 0.39–1.24) and time delay (HR 1.02) showed no significant effect on event-free survival.
Secondary analysis
Liu et al. Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial